Primary immunosuppression with tacrolimus in renal transplantation: A multicenter, open-label study

A multicenter, prospective, open-label trial was performed to assess the ef ficacy and safety of tacrolimus for primary immunosuppression in renal tran splantation. Twenty patients were evaluated after receiving cadaveric and l iving, related or unrelated kidney transplants and were monitored for 6 mon ths for patient and graft survival, incidence of acute rejection, and incid ence of adverse events. Tacrolimus at a final mean dose of 0.11 mg/kg per d ay was 100% effective in preventing acute rejection in this Mexican populat ion. Treatment was associated with a low incidence (10%) of posttransplant diabetes mellitus.